



— **FACT BOOK** —
Supplementary Materials
Financial Results <2Q FY2013>

Otsuka Holdings Co., Ltd.

Corporate Philosophy

Otsuka-people creating new products for better health worldwide

These words embody our commitment to:

- Creating our own unique and innovative products
- Improving human health and well-being
- Contributing to the lives of people worldwide

In keeping with this corporate philosophy and Otsuka's mottoes "*JISSHO*" (Proof through Execution) and "*SOZOSEI*" (Creativity), we strive to utilize our Group's unique assets and skills to develop differentiating scientific solutions which contribute to the lives of people worldwide in the form of innovative and creative products ranging from pharmaceuticals to consumer products.

Otsuka Group is striving to cultivate a culture and a dynamic corporate climate reflecting our vision as a health-care company. As such we are dedicated to achieving global sustainability, to our relationships with local communities and to the protection of the natural environment.


Corporate profile

Company name	Otsuka Holdings Co., Ltd.
Established	July 8, 2008
President and Representative Director, CEO	Tatsuo Higuchi
Capital	JPY 81,690 million
Registered address	2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan
Tokyo headquarters	Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8241, Japan
URL	http://www.otsuka.com/en/


			Page
I	Financial Highlights	• • • • •	2
II	Consolidated Statements of Income	• • • • •	4
	II -1 Sales of Major Products	• • • • •	5
	II -2 Segment Information	• • • • •	7
	II -3 Selling, General and Administrative Expenses	• • • • •	8
III	Consolidated Balance Sheets	• • • • •	9
IV	Consolidated Statements of Cash Flows	• • • • •	11
V	Shareholders	• • • • •	12
VI	Pipeline Information	• • • • •	13

I . Financial Highlights


Net Sales
(Billions of yen)




Operating Income
(Billions of yen)



Ordinary Income
(Billions of yen)



R&D Expenses
(Billions of yen)



Financial Highlights

		FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Estimate FY2013
Net sales	(Billions of yen)	955.9	1,084.3	1,127.6	1,154.6	1,218.1	599.0	699.4	1,435.0
	YoY	3.0%	13.4%	4.0%	2.4%	5.5%	1.5%	16.8%	17.8%
Operating income	(Billions of yen)	91.5	98.5	126.3	148.7	169.7	93.4	111.7	215.0
	YoY	-22.6%	7.6%	28.2%	17.7%	14.1%	8.2%	19.6%	26.7%
Ordinary income	(Billions of yen)	96.1	109.1	128.4	152.1	184.5	95.5	122.0	225.0
	YoY	-22.6%	13.5%	17.7%	18.5%	21.3%	11.7%	27.7%	22.0%
Net income	(Billions of yen)	47.1	67.4	82.4	92.2	122.4	62.7	87.0	155.0
	YoY	-23.9%	43.2%	22.1%	11.9%	32.8%	9.5%	38.9%	26.6%
R&D expenses	(Billions of yen)	135.9	151.8	164.7	159.2	192.4	74.3	105.3	220.0
	YoY	33.5%	11.7%	8.4%	-3.3%	20.8%	-3.6%	41.7%	14.4%
Overseas net sales	(Billions of yen)	395.0	525.5	552.5	579.7	622.7	289.4	372.1	808.0
	% of net sales	41.3%	48.4%	49.0%	50.2%	51.1%	48.3%	53.2%	56.3%

		FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q
Total assets	(Billions of yen)	1,298.8	1,458.4	1,589.7	1,666.8	1,779.2	1,689.6	1,864.5
Net assets	(Billions of yen)	863.8	948.5	1,163.3	1,222.8	1,325.1	1,250.9	1,411.9
Shareholders' equity ratio	(%)	62.3	64.2	72.4	72.5	73.7	73.2	74.4

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

(Billions of yen)

Net sales by business segment	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
Net sales	955.9	1,084.3	1,127.6	1,154.6	1,218.1	599.0	699.4	16.8%	1,435.0
Pharmaceutical business*	652.2	715.9	751.1	782.2	850.9	398.1	477.1	19.9%	1,015.0
Nutraceutical business*	219.2	248.8	258.7	254.8	251.8	139.2	155.8	11.9%	288.0
Consumer products business*	52.1	51.1	47.9	49.2	46.9	26.8	24.0	-10.4%	44.0
Other business*	60.1	105.1	106.9	108.6	111.7	57.9	66.1	14.0%	131.0
Eliminations/corporate	-27.6	-36.6	-37.0	-40.3	-43.1	-23.1	-23.7		-43.0

*Intersegment sales are included.

(Billions of yen)

Operating income by business segment	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
Operating income	91.5	98.5	126.3	148.7	169.7	93.4	111.7	19.6%	215.0
Pharmaceutical business	133.6	132.9	142.8	168.5	187.9	96.9	113.2	16.9%	
Nutraceutical business	-5.2	2.3	18.4	22.1	21.4	15.2	17.8	17.1%	
Consumer products business	-3.7	-8.4	-2.2	-2.3	-2.4	-0.6	-1.0	-	
Other business	2.3	4.4	4.4	1.9	3.9	2.6	4.1	58.2%	
Eliminations/corporate	-35.5	-32.7	-37.1	-41.6	-41.0	-20.6	-22.5		

(Reference) Exchange rates used to translate operating results of overseas subsidiaries

(Yen)

Exchange rate (Yen)	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
US\$	91.03	92.10	87.79	79.79	79.80	79.77	95.72	15.95	97.00
Euro	127.96	132.00	116.27	111.12	102.55	103.48	125.62	22.14	128.00

ROE / EPS / Dividend	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
ROE (Return on equity: %)	7.2	7.7	7.9	7.8	9.7	5.1	6.5	1.3	11.3
EPS (Earnings per share: yen)	2,727.2	143.5	164.5	165.2	221.9	113.3	159.9	46.7	285.5
Annual dividends per share (yen)	250.0	12.5	28.0	45.0	58.0	28.0	30.0	2.0	65.0
Payout ratio (%)	9.2%	8.7%	17.3%	27.2%	26.1%	24.7%	18.8%		22.8%

* On June 30, 2009, a twenty-for-one stock split was executed by way of a free share distribution.

(Billions of yen)

Cash flow information	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change
Net cash provided by operating activities	58.5	173.5	87.7	147.6	119.3	69.8	128.4	58.6
Net cash used in investing activities	-213.6	-59.0	-131.5	-107.6	-91.2	-51.9	-2.3	49.6
Net cash provided (used in) by financing activities	172.2	-28.1	113.6	-41.1	-71.9	-55.2	-57.0	-1.8
Cash and cash equivalents at end of period	230.1	321.3	387.3	384.2	347.6	347.8	430.7	82.9

II. Consolidated Statements of Income

(Billions of yen)															
	FY2008	%	FY2009	%	FY2010	%	FY2011	%	FY2012	%	FY2012 1-2Q	%	FY2013 1-2Q	Change	
Net sales	955.9	100.0%	1,084.3	100.0%	1,127.6	100.0%	1,154.6	100.0%	1,218.1	100.0%	599.0	100.0%	699.4	100.0%	16.8%
Cost of sales	322.6	33.7%	356.6	32.9%	379.0	33.6%	389.3	33.7%	393.8	32.3%	196.8	32.8%	215.3	30.8%	9.4%
Gross profit	633.4	66.3%	727.7	67.1%	748.6	66.4%	765.3	66.3%	824.2	67.7%	402.2	67.2%	484.1	69.2%	20.3%
Selling, general and administrative expenses	541.8	56.7%	629.2	58.0%	622.3	55.2%	616.6	53.4%	654.6	53.7%	308.8	51.6%	372.4	53.2%	20.6%
Promotion expenses	158.3		198.7		179.6		174.4		156.2		85.0		86.2		
Salaries and bonuses	68.7		77.9		80.3		81.3		85.4		37.8		48.2		
Reserve for bonuses	9.1		9.9		9.6		9.8		9.5		8.8		9.9		
Retirement benefit expenses	6.1		7.9		7.1		7.7		7.8		3.8		2.3		
Provision for directors' retirement benefits	1.5		0.7		0.6		0.7		0.6		-		-		
Provision for directors' bonuses	0.3		0.3		0.3		0.4		0.3		-		-		
Depreciation	12.4		14.7		14.1		14.7		14.5		-		-		
Amortization of goodwill	2.9		4.3		4.6		4.7		4.8		2.4		1.7		
Research and development expenses	135.9	14.2%	151.8	14.0%	164.7	14.6%	159.2	13.8%	192.4	15.8%	74.3	12.4%	105.3	15.1%	41.7%
Other	146.7		163.0		161.5		163.8		183.0		96.8		118.7		
Operating income	91.5	9.6%	98.5	9.1%	126.3	11.2%	148.7	12.9%	169.7	13.9%	93.4	15.6%	111.7	16.0%	19.6%
Non-operating income	11.0		14.9		10.8		8.6		16.6		6.7		11.5		
Interest income	3.1		1.4		1.3		1.6		1.4		0.7		0.6		
Dividend income	1.0		1.6		1.2		1.3		1.5		0.8		0.5		
Amortization of negative goodwill	2.5		2.5		2.5		2.5		2.5		1.2		1.4		
Equity in earnings of unconsolidated subsidiaries and affiliates	1.8		4.9		3.7		1.2		3.1		2.6		2.9		
Foreign exchange profit, net	-		-		-		-		6.2		-		5.3		
Revenues related to extension of co-promotion agreement	-		1.8		-		-		-		-		-		
Other	2.7		2.7		2.0		2.1		2.0		1.3		0.8		
Non-operating expenses	6.5		4.3		8.6		5.2		1.8		4.6		1.3		
Interest expenses	1.6		3.2		1.5		1.7		1.2		0.8		0.7		
Foreign exchange loss, net	3.0		0.6		5.7		2.7		-		3.6		-		
Other	2.0		0.5		1.4		0.7		0.6		0.2		0.6		
Ordinary income	96.1	10.1%	109.1	10.1%	128.4	11.4%	152.1	13.2%	184.5	15.1%	95.5	15.9%	122.0	17.4%	27.7%
Extraordinary income	2.1		0.4		5.9		1.2		0.3		0.1		1.3		
Gain on sales of fixed assets	0.1		-		0.2		0.2		0.1		0.1		0.4		
Gain on change in equity interest	0.3		-		5.6		0.3		-		-		-		
Gain on abolishment of retirement benefit plan	1.1		-		-		-		-		-		-		
Gain on disposal of recalled products	0.4		-		-		-		-		-		-		
Subsidy	-		0.2		-		-		-		-		0.6		
Other	0.2		0.1		0.1		0.6		0.1		0.0		0.3		
Extraordinary loss	8.1		7.5		11.3		10.9		7.8		1.4		0.4		
Loss on retirement of fixed assets	1.0		1.1		0.9		0.6		0.7		-		0.3		
Impairment loss	1.6		2.4		2.8		2.7		2.6		1.0		0.1		
Loss on valuation of investment securities	4.0		1.6		1.9		3.7		4.4		-		-		
Loss on recall of merchandises	1.0		-		-		-		-		-		-		
Provision of allowance for investment loss	-		1.5		0.6		-		-		-		-		
Loss on transfer of business	-		-		1.9		0.7		-		-		-		
Provision for loss on business liquidation	-		-		-		2.2		-		-		-		
Disaster related loss	-		-		1.8		0.3		-		-		-		
Other	0.6		1.0		1.4		0.8		0.1		0.4		0.1		
Income before income taxes and minority interests	90.1		101.9		123.0		142.4		176.9		94.3		122.8		
Income taxes-current	35.6		52.6		33.6		55.0		62.0		31.2		34.0		
Income taxes-deferred	0.5		-19.2		5.4		-5.4		-8.2		-0.0		0.8		
Total income taxes	36.1		33.5		39.0		49.6		53.8		31.1		34.8		11.8%
Minority interests in net income	6.9		1.0		1.6		0.6		0.7		0.5		1.0		
Net income	47.1	4.9%	67.4	6.2%	82.4	7.3%	92.2	8.0%	122.4	10.1%	62.7	10.5%	87.0	12.4%	38.9%

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

II - 1. Sales of Major Products

【Pharmaceutical business】							(Billions of yen)			
Product name	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
Anti-psychotic agent <i>ABILIFY</i>	Otsuka Pharmaceutical	297.1	374.5	392.6	411.6	438.5	205.4	261.0	27.0%	560.0
USA		237.2	305.6	308.3	316.1	336.1	156.8	206.3	31.6%	443.0
<US\$ million>		<2,606>	<3,303>	<3,512>	<3,960>	<4,208>	<1,964>	<2,154>	9.7%	<4,565>
Japan		13.2	18.8	23.0	24.8	28.6	14.5	15.6	7.8%	33.0
Others		46.7	50.1	61.2	70.7	73.9	34.1	39.0	14.4%	84.0
Anti-platelet agent <i>Pletaal/Pletal</i>	Otsuka Pharmaceutical	46.6	51.5	53.2	50.3	45.8	23.1	23.3	0.9%	42.5
Japan		42.1	45.4	46.5	44.1	40.1	20.2	19.6	-3.2%	35.0
Others		4.5	6.1	6.7	6.2	5.7	2.9	3.8	28.7%	7.5
Anti-gastritis and anti-gastric ulcer agent <i>Mucosta</i>	Otsuka Pharmaceutical	38.3	37.1	30.7	28.7	23.0	11.7	11.3	-3.5%	21.5
Japan		36.2	34.5	27.8	26.0	20.5	10.4	9.7	-6.2%	18.5
Others		2.1	2.6	2.9	2.7	2.5	1.3	1.5	18.3%	3.0
Antimetabolite <i>TS-1</i>	Taiho Pharmaceutical	46.0	37.3	37.1	36.5	37.0	19.3	19.6	1.6%	40.0
Antimetabolite <i>UFT</i>	Taiho Pharmaceutical	25.6	18.3	15.7	12.9	11.2	5.9	5.0	-15.4%	10.0
Reduced folic acid formulation <i>Uzel</i>	Taiho Pharmaceutical	17.7	15.2	14.1	12.7	13.2	6.8	6.2	-9.4%	12.0
Urinary incontinence / frequency treatment <i>P4 (BUP-4)</i>	Taiho Pharmaceutical	10.0	7.6	7.0	6.3	5.6	2.9	2.5	-16.3%	5.5
Oral nutrient for liver failure <i>Aminoleban EN</i>	Otsuka Pharmaceutical	6.2	6.4	6.5	6.1	5.7	2.9	2.8	-3.8%	5.5
Bronchodilator <i>Meptin</i>	Otsuka Pharmaceutical	6.1	5.9	6.1	5.7	5.2	2.4	2.3	-4.3%	5.0
H2-receptor antagonist <i>Protecadin</i>	Taiho Pharmaceutical	6.0	5.1	5.8	6.3	5.9	3.1	2.6	-15.1%	5.5
5-HT ₃ Receptor Antagonist <i>Aloxi</i>	Taiho Pharmaceutical			4.3	7.9	10.0	5.0	5.4	8.4%	11.0
Antineoplastic <i>Abraxane</i>	Taiho Pharmaceutical			1.1	3.2	3.7	1.9	3.9	105.1%	8.5
Antiepileptic <i>E Keppra</i>	Otsuka Pharmaceutical			0.8	4.8	10.5	4.9	7.0	44.1%	15.0
V2-vasopressin receptor antagonist <i>Samsca</i>	Otsuka Pharmaceutical		0.6	3.2	6.7	12.8	5.2	9.4	82.3%	20.5
Anticancer <i>SPRYCEL</i> (collaboration with BMS)	Otsuka Pharmaceutical		2.0	8.0	7.6	12.0	4.2	13.5	221.0%	26.0
Antibiotic <i>Zosyn/Tazocin</i> (bulk supply)	Taiho Pharmaceutical	12.2	11.2	11.2	10.7	12.4	5.5	5.6	2.2%	13.0
Diagnostics -total	Otsuka Pharmaceutical	5.3	8.2	6.6	7.9	8.8	2.8	4.2	49.8%	11.0
Parenteral nutrition (clinical nutrition) -total	Otsuka Pharmaceutical Factory	89.8	92.9	96.8	96.0	96.4	48.7	50.5	3.6%	101.5
Japan		82.4	83.0	87.6	88.6	88.8	45.1	45.7	1.5%	90.0
Others		7.4	9.9	9.2	7.4	7.6	3.6	4.7	29.9%	11.5
Pharmaceutical business -total (excluding exports)	Japan	319.0	312.4	319.9	326.5	351.8	168.7	180.9	7.2%	369.0
Pharmaceutical business -total	Total	651.7	715.9	751.1	782.2	850.9	398.1	477.1	19.9%	1,015.0

* The segment classification of quasi-drugs and nutritional products was changed from the pharmaceutical business to the nutraceutical business in July 2008.

* FY2008 results for Taiho Pharmaceutical are for the 15-month period from January 2008 through March 2009 because of the change in fiscal year end.

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

Product sales - Nutraceutical business

(10 thousand cases)

Products	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 2Q	FY2013 2Q	Change
<i>Pocari Sweat</i> 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical								
Japan		2,987	2,624	3,234	2,912	2,709	1,826	2017	10.4%
Overseas		1,650	1,884	1,597	1,963	2,151	1,012	1307	29.1%
<i>SOYJOY</i> 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical								
Japan		303	187	113	100	88	51	66	29.2%
Overseas		40	46	28	20	12	6	8	30.3%
<i>Oronamin C</i> 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,114	1,042	1,051	1,081	1,067	630	654	3.8%
<i>Calorie Mate</i> 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	387	396	392	351	335	177	174	-1.7%
<i>Tiovita Drink</i> 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	495	428	484	532	489	289	229	-20.6%
<i>Solmack</i> (10 thousand of bottles)	Taiho Pharmaceutical	1,928	1,591	1,571	1,579	1,588	737	722	-2.0%

* FY2008 results for Taiho Pharmaceutical are for the 15-month period from January 2008 through March 2009 because of a change in the fiscal year end.

* Overseas sales include sales of consolidated subsidiaries only.

Product sales - Consumer products business

(10 thousand cases)

Products	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 2Q	FY2013 2Q	Change
Bottled Water 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	1,102	840	674	679	567	344	356	3.7%
<i>NESCAFE</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	818	676	680	616	536	267	231	-13.3%
<i>Match</i> 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	321	332	371	451	521	350	320	-8.5%
Other (tea drinks and other) 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	361	390	267	317	300	156	133	-14.5%

Product sales - Other business

(Billions of yen)

Products	Company	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 2Q	FY2013 2Q	Change
Functional chemicals	Otsuka Chemical	27.0	23.2	26.3	27.9	26.6	13.9	16.9	21.8%
Fine chemicals	Otsuka Chemical	14.6	13.7	12.4	9.3	10.2	4.9	4.7	-5.2%

II -2. Segment Information

Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change
Consolidated sales	955.9	1,084.3	1,127.6	1,154.6	1,218.1	599.0	699.4	16.8%
Pharmaceutical business	651.7	715.9	751.1	782.2	850.9	398.1	477.1	19.9%
Japan	319.0	312.4	319.9	326.5	351.8	168.7	180.9	7.2%
North America	282.9	334.7	349.0	361.1	389.0	179.3	236.0	31.6%
Others	49.9	68.8	82.2	94.7	110.0	50.0	60.3	20.5%
Nutraceutical business	217.9	247.0	256.4	251.3	246.9	137.0	152.9	11.6%
Japan	163.9	142.6	154.1	147.4	142.3	86.7	90.7	4.6%
North America	38.8	47.1	46.8	45.8	49.8	22.4	24.9	11.1%
Others	15.2	57.3	55.6	58.1	54.8	27.9	37.3	33.8%
Consumer products business	51.9	50.1	47.1	48.0	45.2	26.0	24.0	-7.9%
Japan	45.7	44.1	40.9	42.0	39.2	22.8	20.3	-10.8%
North America	6.2	5.4	5.5	5.4	5.4	2.8	3.5	22.8%
Others	0.0	0.6	0.7	0.6	0.6	0.4	0.2	-59.0%
Other business	34.4	71.3	72.9	73.1	75.0	38.0	45.4	19.6%
Japan	32.4	59.7	60.1	59.1	62.0	31.3	35.4	13.0%
North America	0.4	1.3	1.4	1.3	1.4	0.7	1.1	65.1%
Others	1.6	10.4	11.4	12.7	11.6	6.0	8.9	49.3%
Japan -total	560.9	558.8	575.1	574.9	595.3	309.6	327.3	5.7%
North America - total	328.3	388.4	402.7	413.5	445.7	205.2	265.4	29.4%
Others - total	66.7	137.1	149.8	166.2	177.1	84.3	106.7	26.6%
Overseas net sales	395.0	525.5	552.5	579.7	622.7	289.4	372.1	28.6%
Overseas net sales ratio	41.3%	48.4%	49.0%	50.2%	51.1%	48.3%	53.2%	

Net Sales and Operating Income by Geographical Segment

(Billions of yen)

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change
Net sales	955.9	1,084.3	1,127.6	1,154.6	1,218.1	599.0	699.4	16.8%
Japan*	689.0	709.4	745.2	779.1	842.5	409.4	484.0	18.2%
North America*	315.0	406.2	426.0	437.5	474.1	220.2	296.5	34.6%
Others*	55.6	121.6	132.5	142.4	138.2	69.6	97.0	39.4%
Eliminations/corporate	-103.6	-152.8	-176.2	-204.4	-236.7	-100.2	-178.1	

*Intersegment sales are included.

(Billions of yen)

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change
Operating income	91.5	98.5	126.3	148.7	169.7	93.4	111.7	19.6%
Japan	73.8	86.5	106.3	142.5	160.8	85.3	113.9	33.5%
North America	9.9	11.3	12.2	14.4	16.2	4.8	-2.8	-158.9%
Others	5.2	8.4	6.8	3.7	6.4	3.8	3.6	-5.2%
Eliminations/corporate	2.6	-7.7	1.0	-12.0	-13.8	-0.5	-3.0	

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

II - 3. Selling, General and Administrative Expenses

(Billions of yen)

Selling, general and administrative expenses	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
Net sales	955.9	1,084.3	1,127.6	1,154.6	1,218.1	599.0	699.4	16.8%	1,435.0
Selling, general and administrative expenses	541.8	629.2	622.3	616.6	654.6	308.8	372.4	20.6%	780.0
(% of net sales)	56.7%	58.0%	55.2%	53.4%	53.7%	51.6%	53.2%		54.4%
Promotion expenses	158.3	198.7	179.6	174.4	156.2	85.0	86.2	1.5%	
Personnel expenses	85.7	96.7	97.9	99.8	103.7	50.8	60.7	19.6%	
Advertising expenses	30.1	33.2	28.9	25.1	29.5	16.2	19.9	22.5%	
Research and development expenses	135.9	151.8	164.7	159.2	192.4	74.3	105.3	41.7%	220.0
(% of net sales)	14.2%	14.0%	14.6%	13.8%	15.8%	12.4%	15.1%		15.3%
R&D expenses of pharmaceutical business	131.9	141.6	153.4	149.3	183.5	70.2	101.3	44.3%	210.0

(Persons)

Number of employees (consolidated)	FY2008	FY2009	FY2010	FY2011	FY2012	Change
Japan	13,657	14,174	14,030	13,808	13,732	-76
Overseas	9,271	10,415	11,158	10,787	11,598	811
Pharmaceutical business	14,260	13,961	14,662	14,063	14,660	597
Number of sales representatives (Japan)	1,992	2,099	2,240	2,297	2,329	32
Nutraceutical business *	-	5,854	5,740	5,422	5,729	307
Consumer products business *	5,825	928	855	819	831	12
Other business	1,498	2,275	2,218	2,490	2,429	-61
Corporate	1,345	1,571	1,713	1,801	1,681	-120
Number of employees (consolidated)	22,928	24,589	25,188	24,595	25,330	735

* Effective April 1, 2009, the business segmentation was modified.

(Billions of yen)

Capital expenditures	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
Capital expenditures	63.4	62.5	44.8	43.3	63.3	24.4	48.7	24.2	72.0
Pharmaceutical business	16.3	21.1	24.5	20.8	38.0	16.0	39.1	23.0	
Nutraceutical business *	36.8	23.1	11.9	11.5	14.9	3.9	4.6	0.7	
Consumer products business *	0.5	0.8	0.8	2.0	2.7	1.7	1.3	-0.4	
Other business	2.6	7.7	2.9	4.6	4.0	1.7	1.4	-0.3	
Corporate	7.3	9.7	4.7	4.5	3.7	1.1	2.3	1.2	

* Effective April 1, 2009, the business segmentation was modified. The information for FY2008 has been reclassified according to the new segmentation.

- Pharmaceutical business capital expenditures of FY2013 1-2Q includes Claris Otsuka that will be consolidated in FY2013.

- Astex Pharmaceuticals is excluded in capital expenditures estimate of FY2013

(Billions of yen)

Depreciation	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change	Estimate FY2013
Depreciation	40.3	46.6	48.1	48.1	45.5	22.2	23.1	0.9	46.0
Pharmaceutical business	22.3	20.4	22.4	22.8	21.9	10.5	11.1	0.6	
Nutraceuticals business *	10.5	15.1	14.8	13.1	12.1	5.9	6.6	0.6	
Consumer products business *	0.7	1.1	0.9	2.1	2.0	1.0	0.9	-0.1	
Other business	2.5	5.3	5.2	5.1	4.6	2.3	2.2	-0.0	
Eliminations/corporate	4.3	4.7	4.8	5.0	4.9	2.5	2.3	-0.2	

* Effective April 1, 2009, the business segmentation was modified. The information for FY2008 has been reclassified according to the new segmentation.

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

III. Consolidated Balance Sheets

<Assets>

(Billions of yen)

	As of March 31, 2009	As of March 31, 2010	As of March 31, 2011	As of March 31, 2012	As of March 31, 2013	As of Sep 30, 2013	Composition	Change
Current assets	622.3	751.5	921.2	1,012.3	1,080.6	1,130.5	60.6%	49.9
Cash and deposits	235.8	300.7	387.5	411.6	414.4	495.2		80.8
Notes and accounts receivable-trade	225.8	231.7	239.6	263.5	318.1	295.2		-22.9
Marketable securities	12.2	50.2	122.5	151.8	137.8	112.3		-25.5
Finished products and merchandise	55.3	64.2	62.3	60.8	71.2	75.7		4.5
Work-in process	19.5	22.9	23.6	26.9	25.8	31.5		5.6
Raw materials and supplies	29.3	28.3	28.9	31.7	35.3	35.4		0.2
Deferred tax assets	19.9	28.3	24.6	34.3	40.8	-		-
Other	25.1	25.6	32.4	32.2	37.8	85.9		48.1
Allowance for doubtful receivables	-0.5	-0.4	-0.4	-0.4	-0.5	-0.7		-0.1
Fixed assets	676.5	706.8	668.4	654.4	698.5	733.9	39.4%	35.4
Property, plant and equipment	244.3	260.9	256.8	255.5	276.0	307.9		31.9
Intangible fixed assets	86.4	88.4	77.1	67.1	73.9	86.2		12.4
Goodwill	41.6	44.8	41.4	36.8	37.8	40.5		2.7
Other intangible fixed assets	44.8	43.6	35.6	30.3	36.1	45.7		9.7
Investments and other assets	345.7	357.5	334.5	331.8	348.7	339.8		-8.9
Investment securities	273.1	278.5	261.2	267.0	276.3	268.1		-8.2
Investments in capital	23.6	24.3	22.0	23.3	31.6	33.7		2.2
Long-term loans receivable	4.1	3.3	0.6	1.3	0.9	-		-
Deferred tax assets	28.0	34.0	32.2	25.3	26.5	-		-
Other assets	19.7	20.0	21.3	16.3	15.8	39.7		23.9
Allowance for investment loss	-1.3	-2.4	-2.8	-1.0	-1.6	-1.0		0.5
Allowance for doubtful receivables	-1.4	-0.3	-0.1	-0.5	-0.8	-0.7		0.0
Deferred assets	0.0	0.1	0.1	0.1	0.1	0.1	0.0%	0.0
Total assets	1,298.8	1,458.4	1,589.7	1,666.8	1,779.2	1,864.5	100%	85.3

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

<Liabilities>

(Billions of yen)

	As of March 31, 2009	As of March 31, 2010	As of March 31, 2011	As of March 31, 2012	As of March 31, 2013	As of Sep 30, 2013	Composition	Change
Total liabilities	435.0	509.9	426.4	444.0	454.1	452.5	24.3%	-1.6
Current liabilities	233.3	311.8	275.6	311.4	346.5	355.4	19.1%	9.0
Notes and accounts payable-trade	84.2	94.0	88.1	94.8	97.5	114.1		16.6
Short-term borrowings	37.4	62.7	53.2	39.7	51.8	48.8		-3.0
Lease obligations	3.6	3.6	3.4	3.0	2.6	-		-
Income taxes payable	9.3	35.3	13.3	33.8	33.5	32.2		-1.3
Reserve for bonuses	16.0	16.2	15.9	16.1	15.9	16.3		0.3
Provision for directors' bonuses	0.3	0.3	0.3	0.4	0.3	-		-
Provision for sales returns	0.2	0.2	0.1	0.1	0.2	-		-
Other current liabilities	82.3	99.6	101.2	123.4	144.7	144.0		-0.6
Long-term liabilities	201.7	198.1	150.8	132.6	107.7	97.1	5.2%	-10.6
Long-term debt	92.8	62.4	28.8	25.9	6.3	8.6		2.4
Lease obligations	5.6	7.6	7.1	5.8	5.9	-		-
Deferred tax liabilities	15.6	13.2	10.8	8.0	11.3	-		-
Liability for employees' retirement benefits	40.6	45.1	44.3	44.7	40.6	34.7		-5.9
Provision for directors' retirement benefits	3.2	3.3	3.4	3.1	3.1	2.5		-0.6
Negative goodwill	33.9	31.4	28.9	26.5	24.0	22.8		-1.2
Other long-term liabilities	10.0	35.1	27.5	18.7	16.6	28.5		11.8

<Net assets>

Total net assets	863.8	948.5	1,163.3	1,222.8	1,325.1	1,411.9	75.7%	86.9
Shareholders' equity	844.8	962.1	1,202.3	1,267.7	1,342.0	1,390.3	74.6%	48.3
Common stock	42.9	42.9	81.7	81.7	81.7	81.7		0.0
Capital surplus	355.8	432.5	510.6	510.6	510.4	513.0		2.6
Retained earnings	468.1	532.0	610.0	675.4	768.3	843.9		75.6
Treasury stock	-22.1	-45.4	-0.0	-0.0	-18.4	-48.3		-29.9
Valuation and translation adjustments	-35.3	-25.8	-52.1	-59.1	-31.5	-3.1	-0.2%	28.4
Unrealized gain/loss on available-for-sale securities	-0.7	4.3	0.4	0.8	8.3	10.9		2.7
Deferred loss on derivatives under hedge accounting	-	-0.0	-0.0	0.0	0.0	-0.6		-0.6
Foreign currency translation adjustments	-34.6	-30.1	-52.4	-59.9	-39.8	-13.5		26.4
Stock acquisition rights	-	-	0.5	1.1	0.1	0.1	0.0%	0.0
Minority interests	54.4	12.2	12.7	13.0	14.5	24.6	1.3%	10.2
Total liabilities and net assets	1,298.8	1,458.4	1,589.7	1,666.8	1,779.2	1,864.5	100.0%	85.3

IV. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2008	FY2009	FY2010	FY2011	FY2012	FY2012 1-2Q	FY2013 1-2Q	Change
Operating activities:								
Income before income taxes and minority interests	90.1	101.9	123.0	142.4	176.9	94.3	122.8	28.6
Depreciation	37.5	42.8	43.5	43.4	40.6	19.7	21.3	1.6
Impairment loss	1.6	2.4	2.8	2.7	2.6	1.0	0.1	-0.9
Amortization of goodwill	0.5	1.8	2.1	2.2	2.4	1.2	0.3	-0.9
Increase in liability for employees' retirement benefits	0.1	4.2	0.3	0.5	-4.7	-1.6	-6.5	-4.9
Increase in allowance for doubtful receivables	0.1	-0.0	-0.1	0.4	0.2	-0.0	-0.0	0.0
Increase in provision for loss on business liquidation	-	-	-	2.2	-0.3	-	-	-
Interest and dividend income	-4.1	-2.9	-2.5	-2.8	-2.9	-1.6	-1.1	0.5
Interest expenses	1.6	3.2	1.5	1.7	1.2	0.8	0.7	-0.1
Equity in earnings of unconsolidated subsidiaries and affiliates	-1.8	-4.9	-3.7	-1.2	-3.1	-2.6	-2.9	-0.3
Loss on sales of stocks of subsidiaries	-	-	-	-	-	-	-0.3	-0.3
Gain on change in equity interest	-0.3	-	-5.6	-0.3	-	-	-	-
Loss on transfer of business	-	-	1.9	0.7	-	-	-	-
Decrease in accounts receivables-trade	-7.3	0.2	-17.0	-25.7	-47.2	-19.9	37.0	56.9
Increase in inventories	-9.3	-7.4	-7.4	-7.4	-5.5	-9.5	1.7	11.2
Increase in accounts payable-trade	-5.2	5.3	2.1	8.5	-3.9	19.3	7.8	-11.5
Increase in long-term unearned revenue	-	29.9	-7.3	-7.3	-1.9	4.5	-6.4	-10.9
Other, net	5.0	19.1	8.1	17.3	25.7	0.2	-12.6	-12.8
Subtotal	108.4	195.5	141.7	177.2	180.1	105.8	162.0	56.2
Interest and dividends received	6.9	8.9	7.9	6.9	7.2	4.6	4.9	0.3
Interest paid	-1.5	-3.2	-1.8	-2.0	-1.2	-0.8	-0.7	0.1
Income taxes paid	-55.2	-27.7	-59.9	-34.4	-66.8	-39.8	-37.9	1.9
Net cash provided by operating activities	58.5	173.5	87.7	147.6	119.3	69.8	128.4	58.6
Investing activities:								
Increase in short-term investment securities	-	-	-	-7.0	-20.0	-10.6	11.1	21.6
Purchases of property, plant and equipment	-30.2	-39.7	-35.4	-36.0	-50.5	-23.1	-22.5	0.6
Proceeds from sales of property, plant and equipment	0.7	0.2	0.5	0.7	0.3	0.2	0.9	0.8
Purchases of investment securities	-149.5	-28.8	-33.2	-31.4	-16.7	-11.1	-4.2	6.9
Proceeds from sales and redemption of investment securities	11.2	15.7	27.7	17.4	16.2	9.1	7.0	-2.1
Payments for investments in capital	-2.8	-	-1.8	-0.3	-3.3	-2.1	-1.1	1.1
Proceeds from transfer of business	-	-	2.1	1.4	-	-	-	-
Payments for transfer of business	-	-	-	-1.3	-	-	-	-
Purchase of investments in subsidiaries resulting in change in scope of consolidation	-34.5	-	-	-	-1.5	-	-12.8	-12.8
Payments of loans receivables	-1.5	-1.4	-0.3	-2.3	-0.7	-0.2	-1.1	-0.9
Proceeds from collection of loans receivables	0.1	0.1	0.4	0.6	1.4	1.3	0.4	-0.9
Increase in time deposits-net	-5.6	-0.3	-85.8	-47.5	-9.1	-12.8	23.6	36.5
Other, net	-1.7	-4.9	-5.8	-1.9	-7.3	-2.5	-3.6	-1.1
Net cash used in investing activities	-213.6	-59.0	-131.5	-107.6	-91.2	-51.9	-2.3	49.6
Financing activities:								
Increase in short-term debt-net	19.3	13.5	-6.7	3.2	1.1	0.0	-8.0	-8.1
Proceeds from long-term debt	73.6	3.5	2.6	2.3	3.4	2.4	0.9	-1.5
Repayments of long-term debt	-6.4	-27.6	-33.8	-23.8	-16.1	-14.4	-1.5	12.9
Redemption of bonds	-	-7.6	-	-	-	-	-	-
Proceeds from issuance of common stock	94.9	-	77.5	-	-	-	-	-
Proceeds from disposal of treasury stock	-	-	85.2	-	0.2	-	0.1	0.1
Purchases of treasury stock	-	-	-	-	-20.0	-20.0	-30.0	-10.0
Dividends paid	-4.1	-5.9	-6.0	-26.8	-29.3	-13.9	-16.5	-2.6
Dividends paid to minority interest in consolidated subsidiaries	-1.0	-0.9	-0.4	-0.4	-0.5	-0.2	-0.4	-0.2
Other, net	-4.1	-3.1	-4.9	4.5	-10.7	-9.0	-1.5	7.4
Net cash provided by (used in) financing activities	172.2	-28.1	113.6	-41.1	-71.9	-55.2	-57.0	-1.8
Foreign currency translation adjustment on cash and cash equivalents	-9.7	1.0	-5.3	-1.4	6.2	-0.1	4.7	4.8
Net increase in cash and cash equivalents	7.4	87.3	64.5	-2.4	-37.6	-37.4	73.9	111.2
Cash and cash equivalents at beginning of period	222.6	230.1	321.3	387.3	384.2	384.2	347.6	-36.6
Increase in cash and cash equivalents resulting from change of scope of consolidation	0.1	3.9	1.5	-0.7	0.9	0.9	9.2	8.3
Cash and cash equivalents at end of period	230.1	321.3	387.3	384.2	347.6	347.8	430.7	82.9

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

V. Shareholders

【Classification of shareholders】

(As of Sep 30, 2013)

Classification	Shareholder Information								Less than trading unit
	National and local government	Financial institutions	Financial instruments firms	Other institutions	Foreign investors		Private investors and others	Total	
					Other than individuals	Individuals			
Number of shareholders	-	100	46	463	481	19	46,043	47,152	-
Number of shares held (shares)	-	1,580,478	45,107	1,024,728	1,259,622	190	1,666,633	5,576,758	159,817
% of outstanding shares	-	28.34%	0.81%	18.37%	22.59%	0.00%	29.89%	100.00%	-

*Out of 16,323,351 shares of treasury stock, 163,233 share units are included in “Private investors and others”, and 51 shares are included in “Less than trading unit”

【Principal shareholders】

(As of Sep 30, 2013)

Names	Address	Number of shares held	% of outstanding shares
		(thousand shares)	
The Nomura Trust & Banking Co. Otsuka Founders Shareholding Fund Trust Account	2-2-2 Otemachi, Chiyoda-ku, Tokyo	64,936	11.64
Japan Trustee Services Bank, Ltd. (Trust Account)	8-11, Harumi 1-Chome, Chuo-ku, Tokyo	42,783	7.67
Otsuka Estate Limited	3-3-3 Ote-Dori, Chuo-ku, Osaka	24,011	4.30
Otsuka Group Employee Shareholding Fund	2-16-4 Konan, Minato-ku, Tokyo	20,867	3.74
The Master Trust Bank of Japan, Co., Ltd. (Trust Account)	2-11-3 Hamamatsucho, Minato-ku, Tokyo	14,988	2.68
The Awa Bank, Limited	2-24-1 Nishisemba-cho, Tokushima	10,970	1.96
TOHO HOLDINGS CO., LTD.	5-2-1, Daizawa, Setagaya Ward, Tokyo	7,270	1.30
Otsuka Asset Co., Ltd.	17-4, Aza-Fukuike, Tosadamariura, Naruto-cho, Naruto City, Tokushima	7,220	1.29
The Chase Manhattan Bank, N.A. London S.L. Omnibus Account (Standing proxy: Custody & Proxy Department, Mizuho Bank, Ltd.)	WOOLGATE HOUSE, COLEMAN STREET LONDON EC2P 2HD, ENGLAND (4-16-13 tsukishima, chuo-ku, Tokyo)	6,305	1.13
The Bank of New York, Treaty JASDEC Account (Standing proxy: Bank of Tokyo-Mitsubishi UFJ)	AVENEU DES ARTS, 35 KUNSTLAAN, 1040 BRUSSELS, BELGIUM (1-7-2 marunouchi chiyoda-ku Tokyo)	6,290	1.12
ALL	—	205,644	36.86

16,323,351 shares of treasury stock are excluded from principal shareholders, but included in calculating percentage of outstanding shares.

VI. Pipeline Information

Otsuka Group – Pipeline Information

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country/ Region	Development status
Central nervous system						
OPC-14597 <ABILIFY*> <Abilify Maintena*>:Depot injection	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Schizophrenia / Depot Injection	EU JP	Filed Phase III
				Autism / Oral	JP	Phase III
				Tourette's disorder / Once-weekly Tablet	US	Phase III
				Bipolar I / Depot injection	JP, US, EU	Phase III
L059 <EKEPPRA*>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral	JP	Phase III
				Epilepsy (partial onset seizures) / injection	JP	Filed
				Epilepsy (partial onset seizures/mono therapy) / Oral	JP	Phase III
OPC-34712	brexipiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Adjunctive therapy for major depressive disorder / Oral	US, EU	Phase III
				Schizophrenia / Oral	JP, US, EU	Phase III
				ADHD (Adults) / Oral	US	Phase II
				Agitation associated with Dementia of the Alzheimer's type / Oral	US, EU	Phase III

Note 1: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

Note 2: Product names with asterisk "*" are the names used outside Japan.

Code / <Brand name>	Generic name	Origin	Category	Indication/Dosage form	Country/Region	Development status
Anti-cancer and cancer-supportive care						
ABI-007 <Abraxane>	paclitaxel protein-bound particles for injectable suspension	Celgene	Anti-cancer (nanoparticle)	Pancreatic cancer / Injection	JP	Phase I / II
S-1 <TS-1> Japan, Korea <TEYSUNO*> EU <TS-ONE*> Singapore <愛斯方*> China <愛斯萬*> Taiwan	tegafur, gimeracil, oteracil potassium	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Gastric cancer / Oral Uterocervical cancer / Oral Hepatocellular carcinoma / Oral Renal cell carcinoma / Oral	US JP, Asia JP JP	Phase III Phase III Phase III Phase II
TSU-68	orantinib	(Sugen)	Anti-cancer (Molecular-targeted drug)	Hepatocellular carcinoma / Oral	JP, Asia	Phase III
TAS-102		Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral SCLC / Oral	JP, US, EU JP, EU	Filed Phase III Phase II
TAS-118	tegafur, gimeracil, oteracil potassium, calcium folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
<SATIVEX*>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
OTS102	elpamotide	OncoTherapy Science	Therapeutic cancer vaccine	Biliary tract cancer / Injection	JP	Phase II
OCV-101		OncoTherapy Science	Therapeutic cancer vaccine	Pancreatic cancer / Injection	JP	Phase II
<SPRYCEL>	dasatinib	BMS	Anti-cancer	Pancreatic cancer / Oral	US, EU	Phase II
ET-743	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Phase II
TAS-106		Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Solid tumors / Injection	US	Phase I / II
OPB-31121		Otsuka Pharmaceutical	Anti-cancer	Anti-cancer / Oral	JP, Asia	Phase I
OPB-51602		Otsuka Pharmaceutical	Anti-cancer	Anti-cancer / Oral	US, JP, Asia	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary Prevention of elderly acute myeloid leukemia / Injection	JP	Phase I
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal Cancer / Injection	JP	Phase I

Note 1: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

Note 2: Product names with asterisk "*" are the names used outside Japan.

Otsuka Group – Pipeline Information

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Cardiovascular						
OPC-41061 <SAMSCA*>	tolvaptan	Otsuka Pharmaceutical	Vasopressin V ₂ -receptor antagonist	Hepatic edema / Oral	JP Asia	Approval Filed
				Autosomal dominant polycystic kidney disease / Oral	US, JP EU	Filed** Phase II - III
				Cardiac edema / Oral	Asia	Phase III
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
				Volume overload in peritoneal dialysis / Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
Other areas						
YP-18 <ZOSYN*>	tazobactam sodium· piperacillin sodium	Taiho Pharmaceutical	β-lactamase inhibitor- antibiotic agent	Febrile neutropenia / Injection	JP	Phase III
TAC-202	bilastine	Faes Farma	Histamine H1 Antagonist	allergic rhinitis	JP	Phase II
OPC-67683	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	EU, JP JP, US, EU	Filed Phase III
				Multidrug-resistant tuberculosis for pediatrics / Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
				Keratoconjunctival epithelial disorder / Eye drops UD (Unit Does)	JP	Phase II
OPB-2045G	gluconate olanexidin	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Phase III
OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP, US, Asia	Phase II
ACU-4429	emixustat hydrochloride	Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II b / III
OPA-6566		Otsuka Pharmaceutical	Adenosine A2a receptor agonist	Glaucoma / Eye Drops	US	Phase I / II
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic Dermatitis / Ointment	US	Phase I
Diagnostics						
C13-URA	Uracil (2-13C)	Otsuka Pharmaceutical	13C-uracil breath test	For the diagnosis of gastric emptying disorders / In-vivo diagnostic drug	US	Phase II

Note 1: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

Note 2: Product names with asterisk "*" are the names used outside Japan.

Note 3: ** Otsuka received complete response letter from FDA in August 2013. Otsuka continues future discussion with FDA.



Otsuka-people creating new products
for better health worldwide